438 Studies Now Enrolling
A One Month, investigator and participant-blinded study to investigate the efficacy and safety of remibrutinib (LOU064) at multiple dose levels in adult participants with peanut allergy
Study of Remibrutinib (LOU064) in Patients with Peanut Allergy
| Sponsor: | NOVARTIS Pharmaceuticals |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAU7135 |
| U.S. Govt. ID: | NCT05432388 |
| Contact: | Yannett Franklin: 212-305-2300 / ym206@cumc.columbia.edu |
Additional Study Information:
The study population includes up to 110 adult male and female participants ages 18-55 years. Participants may have multiple food allergies but must be peanut allergic in order to be included. Safety assessments will include the following: physical examination, vital signs, laboratory evaluations, and ECG (electrocardiogram).
